InMed Pharmaceuticals (INM) Other Non-Current Liabilities (2020 - 2021)
InMed Pharmaceuticals (INM) reported Other Non-Current Liabilities of $1.8 million for Q1 2021, little changed quarter-over-quarter from $1.8 million in Q4 2020.
InMed Pharmaceuticals (INM) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
InMed Pharmaceuticals has reported Other Non-Current Liabilities for 2 years, with the latest figure at $1.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.76 Mn |
| Dec 31, 2020 | 1.76 Mn |